Quantitative Proteome Responses to Oncolytic Reovirus in GM-CSF-and M-CSF-Differentiated Bone Marrow-Derived Cells

Michael A. Giacomantonio, Andra M. Sterea, Youra Kim, Joao A. Paulo, Derek R. Clements, Barry E. Kennedy, Moamen J. Bydoun, Ge Shi, David M. Waisman, Steven P. Gygi, Carman A. Giacomantonio, J. Patrick Murphy, Shashi Gujar

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

The efficacy of oncolytic viruses (OVs), such as reovirus, is dictated by host immune responses, including those mediated by the pro-versus anti-inflammatory macrophages. As such, a detailed understanding of the interaction between reovirus and different macrophage types is critical for therapeutic efficacy. To explore reovirus-macrophage interactions, we performed tandem mass tag (TMT)-based quantitative temporal proteomics on mouse bone marrow-derived macrophages (BMMs) generated with two cytokines, macrophage colony stimulating factor (M-CSF) and granulocytic-macrophage colony stimulating factor (GM-CSF), representing anti-and proinflammatory macrophages, respectively. We quantified 6863 proteins across five time points in duplicate, comparing M-CSF (M-BMM) and GM-CSF (GM-BMM) in response to OV. We find that GM-BMMs have lower expression of key intrinsic proteins that facilitate an antiviral immune response, express higher levels of reovirus receptor protein JAM-A, and are more susceptible to oncolytic reovirus infection compared to M-BMMs. Interestingly, although M-BMMs are less susceptible to reovirus infection and subsequent cell death, they initiate an antireovirus adaptive T cell immune response comparable to that of GM-BMMs. Taken together, these data describe distinct proteome differences between these two macrophage populations in terms of their ability to mount antiviral immune responses.

Original languageEnglish
Pages (from-to)708-718
Number of pages11
JournalJournal of Proteome Research
Volume19
Issue number2
DOIs
Publication statusPublished - Feb 7 2020

Bibliographical note

Funding Information:
This work was supported by grants from the Canadian Cancer Society Research Institute (CCSRI), Canadian Institutes of Health Research (CIHR), and the Terry Fox Research Institute (TFRI). M.A.G. is a trainee in the Cancer Research Training Program (CRTP) of the Beatrice Hunter Cancer Research Institute (BHCRI), with funds provided by the QEII Health Sciences Centre Foundation and the GIVETOLIVE Becky Beaton Award. J.P.M. and B.E.K. are supported through the BHCRI. D.R.C. and Y.K. are supported by CIHR. S.G. is supported by the Dalhousie Medical Research Foundation (DMRF).

Funding Information:
This work was supported by grants from the Canadian Cancer Society Research Institute (CCSRI), Canadian Institutes of Health Research (CIHR), and the Terry Fox Research Institute (TFRI). M.A.G. is a trainee in the Cancer Research Training Program (CRTP) of the Beatrice Hunter Cancer Research Institute (BHCRI), with funds provided by the QEII Health Sciences Centre Foundation and the GIVETOLIVE Becky Beaton Award. J.P.M. and B.E.K. are supported through the BHCRI. D.R.C. and Y.K. are supported by CIHR. S.G. is supported by the Dalhousie Medical Research Foundation (DMRF).

Publisher Copyright:
Copyright © 2019 American Chemical Society.

ASJC Scopus Subject Areas

  • Biochemistry
  • General Chemistry

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint

Dive into the research topics of 'Quantitative Proteome Responses to Oncolytic Reovirus in GM-CSF-and M-CSF-Differentiated Bone Marrow-Derived Cells'. Together they form a unique fingerprint.

Cite this